INC Research Holdings (INCR) and Idera Pharmaceuticals (IDRA) Critical Survey
INC Research Holdings (NASDAQ: INCR) and Idera Pharmaceuticals (NASDAQ:IDRA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.
This table compares INC Research Holdings and Idera Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|INC Research Holdings||5.69%||40.69%||9.87%|
Earnings & Valuation
This table compares INC Research Holdings and Idera Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|INC Research Holdings||$1.03 billion||2.82||$226.74 million||$1.61||33.26|
|Idera Pharmaceuticals||$16.17 million||22.95||-$42.73 million||($0.33)||-7.51|
INC Research Holdings has higher revenue and earnings than Idera Pharmaceuticals. Idera Pharmaceuticals is trading at a lower price-to-earnings ratio than INC Research Holdings, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
54.6% of INC Research Holdings shares are owned by institutional investors. Comparatively, 30.9% of Idera Pharmaceuticals shares are owned by institutional investors. 0.2% of INC Research Holdings shares are owned by insiders. Comparatively, 30.3% of Idera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
INC Research Holdings has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Idera Pharmaceuticals has a beta of 2.24, indicating that its stock price is 124% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for INC Research Holdings and Idera Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|INC Research Holdings||0||5||4||0||2.44|
INC Research Holdings currently has a consensus price target of $63.50, suggesting a potential upside of 18.58%. Idera Pharmaceuticals has a consensus price target of $5.02, suggesting a potential upside of 102.42%. Given Idera Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Idera Pharmaceuticals is more favorable than INC Research Holdings.
INC Research Holdings beats Idera Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About INC Research Holdings
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers a range of clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
About Idera Pharmaceuticals
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.
Receive News & Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.